

6. Literaturverzeichnis

- Abbracchio, M. P., J. M. Boeynaems, et al. (2003). "Characterization of the UDP-glucose receptor (re-named here the P2Y₁₄ receptor) adds diversity to the P2Y receptor family." *Trends Pharmacol Sci* 24(2): 52-5.
- Abbracchio, M. P. and G. Burnstock (1994). "Purinoceptors: are there families of P2X and P2Y purinoceptors?" *Pharmacol Ther* 64(3): 445-75.
- Agha, A., H. Schluter, et al. (1992). "A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives." *J Vasc Res* 29(3): 281-9.
- Alderman, M. H. (1994). "Non-pharmacological treatment of hypertension." *Lancet* 344(8918): 307-11.
- Ashton, K. J., U. Nilsson, et al. (2003). "Effects of aging and ischemia on adenosine receptor transcription in mouse myocardium." *Biochem Biophys Res Commun* 312(2): 367-72.
- Aumeerally, N., G. Allen, et al. (2004). "Glutamate-evoked release of adenosine and regulation of peripheral nociception." *Neuroscience* 127(1): 1-11.
- Bean, B. P. (1992). "Pharmacology and electrophysiology of ATP-activated ion channels." *Trends Pharmacol Sci* 13(3): 87-90.
- Beilin, L. J. and I. B. Puddey (1992). "Alcohol and hypertension." *Clin Exp Hypertens A* 14(1-2): 119-38.
- Belhassen, B. and A. Pelleg (1984). "Acute management of paroxysmal supraventricular tachycardia: verapamil, adenosine triphosphate or adenosine?" *Am J Cardiol* 54(1): 225-7.
- Burnstock, G. (2000). "P2X receptors in sensory neurones." *Br J Anaesth* 84(4): 476-88.
- Burnstock, G. and J. J. Warland (1987). "P2-purinoceptors of two subtypes in the rabbit mesenteric artery: reactive blue 2 selectively inhibits responses mediated via the P2_y-but not the P2_x-purinoceptor." *Br J Pharmacol* 90(2): 383-91.
- Busse, R., A. Ogilvie, et al. (1988). "Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate in isolated arteries." *Am J Physiol* 254(5 Pt 2): H828-32.
- Chan, C. M., R. J. Unwin, et al. (1998). "Localization of P2X₁ purinoceptors by autoradiography and immunohistochemistry in rat kidneys." *Am J Physiol* 274(4 Pt 2): F799-804.
- Dalziel, H. H. and D. P. Westfall (1994). "Receptors for adenine nucleotides and nucleosides: subclassification, distribution, and molecular characterization." *Pharmacol Rev* 46(4): 449-66.

- Danielson, M. and B. Dammstrom (1981). "The prevalence of secondary and curable hypertension." *Acta Med Scand* 209(6): 451-5.
- Davies, G., R. J. MacAllister, et al. (1995). "Effect of diadenosine phosphates on human umbilical vessels: novel platelet-derived vasoconstrictors." *Br J Clin Pharmacol* 40(2): 170-2.
- Duarte-Araujo, M., C. Nascimento, et al. (2004). "Dual effects of adenosine on acetylcholine release from myenteric motoneurons are mediated by junctional facilitatory A(2A) and extrajunctional inhibitory A(1) receptors." *Br J Pharmacol* 141(6): 925-34.
- Evans, R. J., C. Lewis, et al. (1995). "Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors)." *Mol Pharmacol* 48(2): 178-83.
- Falkner, B. (1991). "Blood pressure response to mental stress." *Am J Hypertens* 4(11): 621S-623S.
- Flodgaard, H. and H. Klenow (1982). "Abundant amounts of diadenosine 5',5''-P1,P4-tetraphosphate are present and releasable, but metabolically inactive, in human platelets." *Biochem J* 208(3): 737-42.
- Forette, F., M. L. Seux, et al. (1998). "Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial." *Lancet* 352(9137): 1347-51.
- Hall, D. A. and S. M. Hourani (1993). "Effects of analogues of adenine nucleotides on increases in intracellular calcium mediated by P2T-purinoceptors on human blood platelets." *Br J Pharmacol* 108(3): 728-33.
- Harden, T. K., J. L. Boyer, et al. (1995). "P2-purinergic receptors: subtype-associated signaling responses and structure." *Annu Rev Pharmacol Toxicol* 35: 541-79.
- Harrison, M. J. and R. Brossmer (1975). "Inhibition of platelet aggregation and the platelet release reaction by alpha, omega diadenosine polyphosphates." *FEBS Lett* 54(1): 57-60.
- Heidenreich, S., M. Tepel, et al. (1995). "Regulation of rat mesangial cell growth by diadenosine phosphates." *J Clin Invest* 95(6): 2862-7.
- Hervas, C., R. Perez-Sen, et al. (2005). "Presence of diverse functional P2X receptors in rat cerebellar synaptic terminals." *Biochem Pharmacol* 70(5): 770-85.
- Hofbauer, K. G., H. Zschiedrich, et al. (1973). "Conversion of angiotensin I into angiotensin II in the isolated perfused rat kidney." *Clin Sci* 44(5): 447-56.

- Hogaboom, G. K., J. P. O'Donnell, et al. (1980). "Purinergic receptors: photoaffinity analog of adenosine triphosphate is a specific adenosine triphosphate antagonist." *Science* 208(4449): 1273-6.
- Hollopeter, G., H. M. Jantzen, et al. (2001). "Identification of the platelet ADP receptor targeted by antithrombotic drugs." *Nature* 409(6817): 202-7.
- Houston, D. A., G. Burnstock, et al. (1987). "Different P2-purinergic receptor subtypes of endothelium and smooth muscle in canine blood vessels." *J Pharmacol Exp Ther* 241(2): 501-6.
- Hoyle, C. H., G. E. Knight, et al. (1990). "Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli." *Br J Pharmacol* 99(3): 617-21.
- Inoue, K. (2006). "The function of microglia through purinergic receptors: Neuropathic pain and cytokine release." *Pharmacol Ther* 109(1-2): 210-26.
- Jankowski, J., M. S. Yoon, et al. (2001). "Vasoactive diadenosine polyphosphates in human placenta: possible candidates in the pathophysiology of pre-eclampsia?" *J Hypertens* 19(3 Pt 2): 567-73.
- Khakh, B. S., G. Burnstock, et al. (2001). "International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits." *Pharmacol Rev* 53(1): 107-18.
- Klag, M. J., P. K. Whelton, et al. (1996). "Blood pressure and end-stage renal disease in men." *N Engl J Med* 334(1): 13-8.
- Koren, M. J., R. B. Devereux, et al. (1991). "Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension." *Ann Intern Med* 114(5): 345-52.
- Lambrecht, G., T. Friebe, et al. (1992). "PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses." *Eur J Pharmacol* 217(2-3): 217-9.
- Landsberg, L. (1992). "Obesity and hypertension: experimental data." *J Hypertens Suppl* 10(7): S195-201.
- Launer, L. J., K. Masaki, et al. (1995). "The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study." *Jama* 274(23): 1846-51.
- Leff, P., B. E. Wood, et al. (1990). "Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery." *Br J Pharmacol* 101(3): 645-9.

- Lewis, C. J. and R. J. Evans (2000). "Comparison of P2X receptors in rat mesenteric, basilar and septal (coronary) arteries." *J Auton Nerv Syst* 81(1-3): 69-74.
- Lewis, C. J., D. P. Gitterman, et al. (2000). "Effects of diadenosine polyphosphates (Ap(n)As) and adenosine polyphospho guanosines (Ap(n)Gs) on rat mesenteric artery P2X receptor ion channels." *Br J Pharmacol* 129(1): 124-30.
- Louie, S., B. K. Kim, et al. (1988). "Diadenosine 5',5''-P1,P4-tetraphosphate, a potential antithrombotic agent." *Thromb Res* 49(6): 557-65.
- Luo, J., J. Jankowski, et al. (1999). "Identification and characterization of diadenosine 5',5''-P1,P2 -diphosphate and diadenosine 5',5''-P1,P3-triphosphate in human myocardial tissue." *Faseb J* 13(6): 695-705.
- Luo, J., J. Jankowski, et al. (1999). "Identification of diadenosine hexaphosphate in human erythrocytes." *Hypertension* 34(4 Pt 2): 872-5.
- Luo, J., V. Jankowski, et al. (2004). "Endogenous diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate in human myocardial tissue." *Hypertension* 43(5): 1055-9.
- Luthje, J. and A. Ogilvie (1983). "The presence of diadenosine 5',5''-P1,P3-triphosphate (Ap3A) in human platelets." *Biochem Biophys Res Commun* 115(1): 253-60.
- Luthje, J. and A. Ogilvie (1984). "Diadenosine triphosphate (Ap3A) mediates human platelet aggregation by liberation of ADP." *Biochem Biophys Res Commun* 118(3): 704-9.
- MacKenzie, A. B., M. P. Mahaut-Smith, et al. (1996). "Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets." *J Biol Chem* 271(6): 2879-81.
- Manzini, S., C. H. Hoyle, et al. (1986). "An electrophysiological analysis of the effect of reactive blue 2, a putative P2-purinoceptor antagonist, on inhibitory junction potentials of rat caecum." *Eur J Pharmacol* 127(3): 197-204.
- Martin, G. N., S. A. Thom, et al. (1991). "The effects of adenosine triphosphate (ATP) and related purines on human isolated subcutaneous and omental resistance arteries." *Br J Pharmacol* 102(3): 645-50.
- Motte, S., D. Communi, et al. (1995). "Involvement of multiple receptors in the actions of extracellular ATP: the example of vascular endothelial cells." *Int J Biochem Cell Biol* 27(1): 1-7.
- Obrador, G. T. and B. J. Pereira (1998). "Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure." *Am J Kidney Dis* 31(3): 398-417.

- Ogilvie, A., R. Blasius, et al. (1996). "Adenine dinucleotides: a novel class of signalling molecules." *J Auton Pharmacol* 16(6): 325-8.
- Pohl, U., K. Herlan, et al. (1991). "EDRF-mediated shear-induced dilation opposes myogenic vasoconstriction in small rabbit arteries." *Am J Physiol* 261(6 Pt 2): H2016-23.
- Quinn, M. J. and D. J. Fitzgerald (1999). "Ticlopidine and clopidogrel." *Circulation* 100(15): 1667-72.
- Ralevic, V. (2000). "P2 receptors in the central and peripheral nervous systems modulating sympathetic vasomotor tone." *J Auton Nerv Syst* 81(1-3): 205-11.
- Ralevic, V. and G. Burnstock (1991). "Roles of P2-purinoceptors in the cardiovascular system." *Circulation* 84(1): 1-14.
- Ralevic, V. and G. Burnstock (1996). "Discrimination by PPADS between endothelial P2Y- and P2U-purinoceptors in the rat isolated mesenteric arterial bed." *Br J Pharmacol* 118(2): 428-34.
- Ralevic, V. and G. Burnstock (1998). "Receptors for purines and pyrimidines." *Pharmacol Rev* 50(3): 413-92.
- Ralevic, V., C. H. Hoyle, et al. (1995). "Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries." *J Physiol* 483 (Pt 3): 703-13.
- Rees, D. A., M. F. Scanlon, et al. (2003). "Novel insights into how purines regulate pituitary cell function." *Clin Sci (Lond)* 104(5): 467-81.
- Rudnick, K. V., D. L. Sackett, et al. (1977). "Hypertension in a family practice." *Can Med Assoc J* 117(5): 492-7.
- Schluter, H., I. Grobeta, et al. (1998). "Adenosine(5') oligophospho-(5') guanosines and guanosine(5') oligophospho-(5') guanosines in human platelets." *J Clin Invest* 101(3): 682-8.
- Schluter, H., E. Offers, et al. (1994). "Diadenosine phosphates and the physiological control of blood pressure." *Nature* 367(6459): 186-8.
- Schluter, H., M. Tepel, et al. (1996). "Vascular actions of diadenosine phosphates." *J Auton Pharmacol* 16(6): 357-62.
- Schulze-Lohoff, E., S. Zanner, et al. (1995). "Vasoactive diadenosine polyphosphates promote growth of cultured renal mesangial cells." *Hypertension* 26(6 Pt 1): 899-904.
- Sinclair, A. M., C. G. Isles, et al. (1987). "Secondary hypertension in a blood pressure clinic." *Arch Intern Med* 147(7): 1289-93.

- Stamler, J., R. Stamler, et al. (1993). "Blood pressure, systolic and diastolic, and cardiovascular risks. US population data." *Arch Intern Med* 153(5): 598-615.
- Steinmetz, M., T. Van Le, et al. (2005). "Prior vasorelaxation enhances diadenosine polyphosphate-induced contractility of rat mesenteric resistance arteries." *Naunyn Schmiedebergs Arch Pharmacol* 371(5): 359-63.
- Szczepanska-Konkel, M., M. Jankowski, et al. (2005). "Effects of diadenosine polyphosphates on glomerular volume." *Br J Pharmacol* 144(8): 1109-17.
- Troade, J. D. and S. Thirion (2002). "Multifaceted purinergic regulation of stimulus-secretion coupling in the neurohypophysis." *Neuro Endocrinol Lett* 23(4): 273-80.
- van der Giet, M., O. Cinkilic, et al. (1999). "Evidence for two different P2X-receptors mediating vasoconstriction of Ap5A and Ap6A in the isolated perfused rat kidney." *Br J Pharmacol* 127(6): 1463-9.
- Van Der Giet, M., G. Giebing, et al. (2002). "The Role of P2Y Receptors in the Control of Blood Pressure." *Drug News Perspect* 15(10): 640-646.
- van der Giet, M., M. Khattab, et al. (1997). "Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney." *Br J Pharmacol* 120(8): 1453-60.
- van der Giet, M., S. Schmidt, et al. (2002). "Effects of dinucleoside polyphosphates on regulation of coronary vascular tone." *Eur J Pharmacol* 448(2-3): 207-13.
- van der Giet, M., T. Westhoff, et al. (2001). "The critical role of adenosine and guanosine in the affinity of dinucleoside polyphosphates to P(2X)-receptors in the isolated perfused rat kidney." *Br J Pharmacol* 132(2): 467-74.
- Vasan, R. S., E. J. Benjamin, et al. (1995). "Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective." *J Am Coll Cardiol* 26(7): 1565-74.
- Wildman, S. S., S. G. Brown, et al. (1999). "Selectivity of diadenosine polyphosphates for rat P2X receptor subunits." *Eur J Pharmacol* 367(1): 119-23.
- Wu, G., G. T. Whiteside, et al. (2004). "A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats." *Eur J Pharmacol* 504(1-2): 45-53.
- Ziganshin, A. U., C. H. Hoyle, et al. (1993). "PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder." *Br J Pharmacol* 110(4): 1491-5.